Centre Plans To Restrict New TB Drugs To Govt Channels, Bar Private Sale
Experts fear that unregulated access could lead to indiscriminate use, risking treatment failures and accelerating the development of drug resistance
The central government is considering a proposal to tighten the regulation of critical anti- tuberculosis (TB) drugs—Bedaquiline, Delamanid, Pretomanid, and Rifapentine—in India's private healthcare market following growing concerns of misuse and drug resistance, News18 has learnt.
The panel of experts, the Drug Consultative Committee (DCC), has recommended that the manufacture and sale of anti-TB drugs should be allowed conditionally. Overall, the idea is to bar manufacturers from selling the drugs in the private market, including pharmacies, hospitals, and clinics, unless they procure them via the government under the National TB Elimination Programme (NTEP).
The move comes after the Central Drugs Standard Control Organisation (CDSCO) received a letter from the Central TB Division, Ministry of Health and Family Welfare, warning that the expiry of patents on Bedaquiline and Delamanid in 2023 has triggered a surge in their production by multiple pharmaceutical companies, making them freely available in the private sector. Experts fear that this unregulated access could lead to indiscriminate use, risking treatment failures and accelerating the development of drug resistance.
Why is this move important?
According to WHO's Global TB Report, India has made significant progress in fighting tuberculosis. Under the NTEP, the incidence rate of TB cases has dropped by nearly 17.7%, from 237 cases per 1 lakh people in 2015 to 195 in 2023. TB-related deaths have also reduced, falling from 28 to 22 per 1 lakh people during the same period.
'We have been making significant progress in eliminating TB. If anti-TB drugs are made available via the private market, there is a high chance of people consuming these drugs without medical supervision. We cannot afford to create drug resistance against the available options," said a senior official working on NTEP.
The step
To curb this fear, the Union Ministry of Health and Family Welfare has recommended that the manufacturing and sale of these drugs be conditional. Specifically, they should be permitted only in accordance with the Standards of TB Care in India (STCI) and made available through conditional access via the National TB Elimination Programme (NTEP). If existing licenses do not reflect this condition, the proposal calls for their immediate modification.
'To mitigate this risk, it has been requested to issue the licenses with a condition for use of Bedaquiline, Delamanid, Pretomanid and Rifapentine as per Standards of TB Care in India (STCI) and conditional access through National TB Elimination programme (NTEP)…," read the minutes of the meeting held on June 17, seen by News18.
Although the drugs have been on the market for over four years—thus no longer qualifying as 'new drugs" which come for approval before the apex Drug Controller General of India (DCGI)—regulators have requested that State Licensing Authorities (SLAs) include these restrictions in all future and past licenses.
Further, the panel agreed that 'the label on the immediate container of the drug as well as the packing in which the container is enclosed should bear the following warning – 'For the use in National TB Elimination Programme (NTEP)' which shall be in a box with a red background."
Also, the panel has agreed to issue uniform guidance to all SLAs. It further advised that SLAs which had already granted licenses for these drugs should send separate letters to manufacturers, informing them of the updated usage conditions. The document has been sent to all relevant health officials by the Drug Controller General of India (DCGI), Dr Rajeev Singh Raghuvanshi, on June 24 for 'taking necessary actions" as per the recommendations decided by the panel.
According to experts, the move is in the right direction. 'It's a good proposal. Globally, we have already seen signs of antibiotic resistance to certain TB drugs, so it's crucial that we take steps in India to prevent it," said Jyotsna Singh, co-convenor, Working Group on Access to Medicines and Treatments, India.
However, Singh added that while this proposal is thoughtful, the government should also look at the continuous stock-outs of TB drugs. 'It's a recurring problem that requires better forecasting and enough money."
First Published:
June 26, 2025, 00:53 IST
News india Centre Plans To Restrict New TB Drugs To Govt Channels, Bar Private Sale
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
9 hours ago
- News18
Braille, Voice-Enabled QR Codes & More: Govt To Set Up Panel To Revamp Medicine Labelling
Last Updated: The concerns submitted to the govt include issues like expiry dates being printed on easily torn paper, reflective surfaces making labels unreadable, and text size being too small. Get ready for voice-assisted QR codes, braille cards, and clearer labels on your medicine strips — the central government is planning a major overhaul of drug packaging to make medicines more patient-friendly, News18 has learnt. To address consumer complaints about the labelling of medicinal products and to make medicine packaging more inclusive for the visually impaired, the drug regulatory agency, Central Drugs Standard Control Organisation (CDSCO), is set to constitute an expert panel. Acting on recommendations from the Drug Consultative Committee (DCC), the CDSCO will now form a sub-committee to examine packaging-related concerns in detail. 'DCC was apprised that various concerns have been received from the consumers in their public grievances from time to time with respect to the labelling of medicinal products," said the government document sent to states and union territories for execution, seen by News18. The concerns submitted to the central government include issues such as expiry dates being printed on easily torn paper, reflective surfaces making labels unreadable, and text size being too small. The concerns submitted to DCC – which discussed the matter in the meeting dated 17 June – also include inconsistent printing of medicine names (only at one place on the entire strip) and the need for a universal symbol to clearly distinguish generic medicines from branded ones. 'The proposed sub-committee will discuss these concerns in detail," said the government official, while adding the panel has asked to include at least one packaging expert and will evaluate whether new regulatory standards are needed for suppliers of packaging materials under the Drugs Rules, 1945. 'The industry is expected to create a pushback as any change in labelling leads to heavy capital expenditure on their end. However, the final move will be decided by the proposed panel." Blind friendly medicine packaging In a related move to improve patient convenience, the DCC also recommended measures to help blind and visually impaired individuals identify medicines. Discussing the proposal regarding the problems faced by the blind or visually impaired people in reading medicines, tablets or capsule strips, DCC was apprised that a similar deliberation was done earlier by the expert panel, which had earlier recommended constituting a panel to examine the issue. Accordingly, that panel had submitted its report. The same report was discussed in the meeting, and now, it will be made public and open for comments, along with the two new suggestions. These include adding braille cards to secondary packaging of medicines containing more than 10 units, and integrating QR codes with voice-assistance features on drug labels. 'Secondary packaging containing more than 10 units of medicines may have some braille cards for giving to such population as and when required," said the first suggestion, while adding the second recommendation stating, 'Medicines can have a QR code linked with voice assistance." Experts believe that, if executed, these developments will mark a significant step towards improving patient safety, accessibility, and transparency in India's pharmaceutical packaging practices. First Published: June 27, 2025, 10:06 IST
Time of India
18 hours ago
- Time of India
Plans to restrict open market access to tuberculosis medicines
With cases of drug-resistant tuberculosis on the rise in India, authorities are set to tighten open market access to newer anti-TB drugs Bedaquiline and Delamanid , which went off patent last year. The Central TB division-which is under the health ministry-had written to the Central Drugs Standard Control Organisation (CDSCO) citing "access risks" that are leading to indiscriminate use, potentially increasing cases of treatment failure and resistance to these drugs. The patents for Bedaquiline and Delamanid expired last year, paving the way for pharmaceutical companies to manufacture the molecule. The drugs eventually became available in the market. The newer anti-TB drugs, including Bedaquiline, Delamanid, Pretomanid and Rifapentine, are available in the market. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Chuck Norris Begs Seniors: Avoid These 3 Foods Like The Plague Roundhouse Provisions Learn More Undo This week, the matter was taken up by the Drugs Consultative Committee (DCC), an expert committee under the CDSCO, which suggested that licences be issued on the condition that the use of Bedaquiline, Delamanid, Pretomanid and Rifapentine will be as per Standards of TB Care in India (STCI), and that there should be conditional access through the National TB Elimination programme (NTEP). The experts also said that if such a condition is not mentioned in the existing licences, it should be modified accordingly. It also said the label on the container of the drug, as well as the packaging, should bear the warning-"For use in NTEP", which shall be in a box with a red background. Live Events "The DCC, after detailed deliberation, agreed with the proposal to issue suitable guidance to all state licensing authorities to address the issue uniformly. The DCC also recommended that in case some SLAs had already issued the manufacturing licence for such a product, they can issue separate letters for communicating the above conditions," the minutes of the meeting suggested. ET has seen a copy of the minutes.
News18
a day ago
- News18
Apple Cider Vinegar Is Not The Magic Bullet You Think It Is!
Last Updated: Apple cider vinegar may support weight loss slightly by boosting metabolism and reducing appetite, but it's no miracle cure for belly fat and must be used with care Apple cider vinegar (ACV) is increasingly popular among those aiming to lose weight, particularly belly fat. Widely promoted across social media and YouTube as a so-called 'miracle' fat burner, many individuals have started taking it regularly, often without professional advice. But does ACV truly help reduce abdominal fat? And if so, what is the correct way to use it? A dietitian weighs in. Dietitian Kamini Sinha of Diet Mantra Clinic, Noida, told News18 that ACV offers certain health benefits due to its acetic acid content. In addition to this key compound, ACV contains potassium, antioxidants, and amino acids. Acetic acid is presumed to have a thermogenic effect, which can marginally boost metabolism and help the body burn more calories, potentially aiding weight loss. It may also reduce appetite, which could lead to lower calorie intake. How To Use ACV Safely According to Kamini Sinha, one to two teaspoons of ACV diluted in a glass of water may be consumed on an empty stomach. While this may contribute to weight management, she clarified that ACV alone has a limited effect on reducing belly fat. It should be viewed as a supplementary aid rather than a standalone solution, best combined with a balanced diet, consistent physical activity, and healthy lifestyle habits. Despite its perceived benefits, ACV should be consumed with caution. Dietitians warn that excessive intake can erode tooth enamel, irritate the throat, and cause digestive issues over time. It must always be diluted and taken in moderation. People with acidity or gastric concerns are advised to avoid it altogether. Experts recommend using ACV for a week or two at a time, followed by an equal break period. First Published: June 26, 2025, 15:14 IST
